Ads
related to: blood test to predict cancer marker images on screen
Search results
Results from the WOW.Com Content Network
The Food and Drug Administration (FDA) has recently approved a blood test screening for colorectal cancer that has an over 83% success rate at detecting the presence of this form of cancer.
Cancer biomarkers have also shown utility in monitoring how well a treatment is working over time. Much research is going into this particular area, since successful biomarkers have the potential of providing significant cost reduction in patient care, as the current image-based tests such as CT and MRI for monitoring tumor status are highly ...
Another colon cancer screening method includes fecal occult blood tests that detect blood in the stool, which can be a warning sign of colon polyps or cancer. The FIT-DNA tests, such as Cologuard ...
Blood-based tests are also more convenient than feces-based tests, such as Exact Sciences' Cologuard, for cancer screening. According to the FDA's documents, a study showed Guardant's Shield test ...
The M2-PK Test is a non-invasive screening method for the early detection of colorectal cancers and polyps which are known to be the precursors of colorectal cancer. The M2-PK Test which is used for stool analysis is available either as fully quantitative ELISA Test or as a rapid test that can be performed by any general practitioner without the need of a laboratory or any additional equipment.
No screening test is wholly specific, and a high level of tumor marker can still be found in benign tumors. The only tumor marker currently used in screening is PSA (prostate-specific antigen). Diagnostics; Tumor markers alone can't be used for diagnostic purposes, due to lack of sensitivity and specificity. [5]
Ads
related to: blood test to predict cancer marker images on screen